TG Therapeutics, Inc.: how funds voted at the meeting of 14 Jun 2024
- Ticker
- TGTX
- Meeting
- Season
- year to 30 June 2024
- Filers reporting
- 324
- Ballot items
- 5
324 filers on Form N-PX reported votes at the TG Therapeutics, Inc. meeting of 14 Jun 2024. The records fall into 5 ballot items. The page lists them in ballot order: items of the company first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting.
This meeting is in the year to 30 June 2024. The latest season on file is the year to 30 June 2026. The page of TG Therapeutics, Inc. has the latest meeting.
If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.
The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .
The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.
The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.
The page gives records. It gives no investment advice and no advice on how to vote.
Season on this page: year to 30 June 2024. Filings read through . How the figures are made
The ballot
Item 1: Director elections
6 nominees. 29.3% of the reported votes are for. 82 filers withheld from or voted against at least one nominee.
986 vote records from 93 filers. 65 of the 93 filers that marked the item voted against management.
- Positions of 30 fund families
- For 5
- Abstain or withhold 25
- Against management 24
Item 2: Advisory vote on executive pay (say-on-pay)
444 vote records from 321 filers. 216 of the 308 filers that marked the item voted against management. 13 filers gave no management mark.
- Positions of 37 fund families
- For 3
- Against 34
- Against management 34
Item 3: Audit-related items (auditor ratification)
166 vote records from 93 filers. 1 of the 93 filers that marked the item voted against management.
- Positions of 30 fund families
- For 30
Item 4: CAPITAL STRUCTURE: management items
The company's items in this category are shown together, because filers word and number them differently.
166 vote records from 93 filers. 41 of the 93 filers that marked the item voted against management.
- Positions of 30 fund families
- For 13
- Against 17
- Against management 17
Item 5: COMPENSATION: management items
The company's items in this category are shown together, because filers word and number them differently.
170 vote records from 96 filers. 3 of the 96 filers that marked the item voted against management.
- Positions of 30 fund families
- For 29
- Against 1
- Against management 1
Positions of the fund families
A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.
KeyForAgainstAbstain or withholdSplit or no voteAgainst management
| Fund family | 2. Say-on-pay | 3. Auditor |
|---|---|---|
| AllianceBernstein | Against, against management | No report |
| Baird | Against, against management | No report |
| BlackRock and iShares | Against, against management | For |
| BNY Mellon | Against, against management | For |
| Brighthouse Funds | Against, against management | For |
| Charles Schwab | Against, against management | For |
| Columbia Threadneedle | Against, against management | No report |
| Dimensional | Against, against management | No report |
| DWS | Against, against management | For |
| Equitable | Against, against management | For |
| Fidelity | Against, against management | For |
| First Trust | Against, against management | For |
| Franklin Templeton | Against, against management | For |
| Global X | Against, against management | For |
| Goldman Sachs | Against, against management | For |
| Guggenheim and Rydex | Against, against management | For |
| Invesco | Against, against management | For |
| J.P. Morgan | Against, against management | For |
| Janus Henderson | Against, against management | No report |
| John Hancock and Manulife | Against, against management | For |
| Lincoln Financial | For | For |
| Morgan Stanley, Eaton Vance and Calvert | Against, against management | For |
| Nationwide | Against, against management | For |
| Neuberger Berman | Against, against management | No report |
| Northern Trust and FlexShares | Against, against management | For |
| Nuveen and TIAA | Against, against management | For |
| Pacific Life funds | Against, against management | For |
| PGIM and Prudential | Against, against management | No report |
| Principal | Against, against management | For |
| ProShares and ProFunds | Against, against management | For |
| Russell Investments | Against, against management | For |
| SEI | Against, against management | For |
| State Street and SPDR | For | For |
| T. Rowe Price | Against, against management | For |
| Vanguard | For | For |
| Victory Capital | Against, against management | For |
| Voya | Against, against management | For |
Questions
- How many filers reported votes at the TG Therapeutics, Inc. meeting?
- 324 Form N-PX filers reported votes at the meeting of 14 Jun 2024. On say-on-pay, 216 of 308 filers that marked the item voted against management (70.1%).
- Is this the result of the meeting?
- No. The page counts the filers that report on Form N-PX, and the shares they reported. TG Therapeutics, Inc. reports the result of a vote on Form 8-K.
- Why does the page show counts only for director elections?
- A director record names the nominee. This site has no page and no row about a person. For director elections it keeps the number of nominees and the split of votes.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list TG Therapeutics, Inc. with a meeting date within three days of 14 Jun 2024. A proposal title is the most common wording among filers. Where a wording can name a person, the SEC category is shown. The filers wrote the filings. Filings read through .